Table 2. Patients baseline characteristics.
GnRH agonists | GnRH antagonists | p-value | |
Age (years) | 30.7±3.88 | 30.5±3.03 | 0.88 |
BMI (kg/m2) | 23.1±2.68 | 22.7±2.80 | 0.72 |
Oestradiol level on day of hCG (nmol/L) | 5.3±2.3 | 4.6±2.4 | 0.48 |
Retrieved oocytes (n) | 11.7±5.24 | 8.0±3.89 | 0.08 |
Degenerated (ratio) | 0.02±0.05 | 0.04±0.11 | 0.46 |
MI (proportion) | 0.07±0.08 | 0.14±0.15 | 0.19 |
MII (proportion) | 0.91±0.08 | 0.82±0.21 | 0.18 |
Fertilized (proportion) | 0.65±0.14 | 0.50±0.19 | 0.06 |
MII-NF (proportion) | 0.68±0.08 | 0.62±0.22 | 0.36 |
MII-BL (proportion) | 0.23±0.08 | 0.20±0.07 | 0.31 |
Endometrial lining thickness (mm) | 9.91±1.58 | 9.8±0.63 | 0.84 |
Pregnancy rate per cycle (proportion) | 0.55±0.16 | 0.60±0.16 | 0.81 |
Delivery rate per cycle (proportion) | 0.55±0.16 | 0.40±0.16 | 0.53 |
Frozen embryos remained (number) | 0.70±0.95 | 0.40±0.70 | 0.43 |
age, body mass index (BMI), serum oestradiol level on day of hCG, number of retrieved oocytes; proportions of degenerated oocytes, metaphase I oocytes (MI), metaphase II oocytes (MII), fertilized oocytes, unfertilized metaphase II oocytes (MII-NF) and metaphase II oocytes developed to the blastocyst stage (MII-BL). Significance of differences between the two treatment groups was assessed using Student's t-test; two-tailed p-values are shown.